A Phase 2, single-arm, open-label study to evaluate the safety and efficacy of MGTA-456 in patients with sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT)
|Effective start/end date||1/1/20 → 12/31/20|
- MEDPACE, INC.
- MAGENTA THERAPEUTICS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.